中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination

文献类型：期刊论文

作者Tang, Ruijing3,4,5; Guo, Luobin3,4,5; Wei, Tingyu3,4,5; Chen, Tingting3,4,5; Yang, Huan3,4,5; Ye, Honghao3,4,5; Lin, Fangzhou3,4,5; Zeng, Yongyi3,4,5; Yu, Haijun1,2; Cai, Zhixiong3,4,5
刊名ELIFE
出版日期2024-09-13
卷号13页码:22
关键词PEG10 CpG-ODN neoantigen Mouse
ISSN号2050-084X
DOI10.7554/eLife.98579
通讯作者Cai, Zhixiong(caizhixiong1985@163.com) ; Liu, Xiaolong(xiaoloong.liu@gmail.com)
英文摘要Tumor neoantigen peptide vaccines hold potential for boosting cancer immunotherapy, yet efficiently co-delivering peptides and adjuvants to antigen-presenting cells in vivo remains challenging. Virus-like particle (VLP), which is a kind of multiprotein structure organized as virus, can deliver therapeutic substances into cells and stimulate immune response. However, the weak targeted delivery of VLP in vivo and its susceptibility to neutralization by antibodies hinder their clinical applications. Here, we first designed a novel protein carrier using the mammalian-derived capsid protein PEG10, which can self-assemble into endogenous VLP (eVLP) with high protein loading and transfection efficiency. Then, an engineered tumor vaccine, named ePAC, was developed by packaging genetically encoded neoantigen into eVLP with further modification of CpG-ODN on its surface to serve as an adjuvant and targeting unit to dendritic cells (DCs). Significantly, ePAC can efficiently target and transport neoantigens to DCs, and promote DCs maturation to induce neoantigen-specific T cells. Moreover, in mouse orthotopic liver cancer and humanized mouse tumor models, ePAC combined with anti-TIM-3 exhibited remarkable antitumor efficacy. Overall, these results support that ePAC could be safely utilized as cancer vaccines for antitumor therapy, showing significant potential for clinical translation.
WOS关键词MESSENGER-RNA ; GAG PROTEIN ; RECEPTOR ; ADJUVANTS ; IMMUNITY ; DEC-205 ; ANTIGEN ; GROWTH ; CELLS
资助项目The National Natural Science Foundation of China[82202027] ; The National Natural Science Foundation of China[U22A20328] ; National Natural Science Foundation of China[2022ZQNZD014] ; Major Research Projects for Young and Middle-aged Talent of Fujian Provincial Health Commission[2022GGA049] ; Young and Middle-aged Talent Training Project of Fujian Provincial Health Commission[2023J06049] ; Young and Middle-aged Talent Training Project of Fujian Provincial Health Commission[2022J011279] ; Scientific Foundation of Fujian Province[2021QH1157] ; Startup Fund for Scientific Research, Fujian Medical University
WOS研究方向Life Sciences & Biomedicine - Other Topics
语种英语
WOS记录号WOS:001313380900001
出版者eLIFE SCIENCES PUBL LTD
源URL[http://119.78.100.183/handle/2S10ELR8/313356]  
专题新药研究国家重点实验室
通讯作者Cai, Zhixiong; Liu, Xiaolong
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
3.Fuzhou Univ, Mengchao Med X Ctr, Fuzhou, Peoples R China
4.Fujian Med Univ, Liver Ctr Fujian Prov, Shanghai, Peoples R China
5.Fujian Med Univ, Mengchao Hepatobiliary Hosp, United Innovat Mengchao Hepatobiliary Technol Key, Fuzhou, Peoples R China
推荐引用方式
GB/T 7714		 Tang, Ruijing,Guo, Luobin,Wei, Tingyu,et al. Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination[J]. ELIFE,2024,13:22.
APA Tang, Ruijing.,Guo, Luobin.,Wei, Tingyu.,Chen, Tingting.,Yang, Huan.,...&Liu, Xiaolong.(2024).Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination.ELIFE,13,22.
MLA Tang, Ruijing,et al."Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination".ELIFE 13(2024):22.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。